Ken Griffin Annexon, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $330,464 - $529,920	-73,600 Reduced 61.8%	45,500 $269,000
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $274,089 - $429,807	63,300 Added 113.44%	119,100 $583,000
Q1 2024 May 15, 2024	BUY	$4.03 - $7.81 $207,142 - $401,434	51,400 Added 1168.18%	55,800 $400,000
Q4 2023 Feb 14, 2024	BUY	$1.63 - $4.63 $6,357 - $18,057	3,900 Added 780.0%	4,400 $19,000
Q3 2023 Nov 14, 2023	SELL	$2.13 - $3.84 $22,365 - $40,320	-10,500 Reduced 95.45%	500 $1,000
Q2 2023 Aug 14, 2023	SELL	$2.1 - $6.37 $8,400 - $25,480	-4,000 Reduced 26.67%	11,000 $38,000
Q1 2023 May 15, 2023	SELL	$3.74 - $7.46 $96,492 - $192,468	-25,800 Reduced 63.24%	15,000 $57,000
Q4 2022 Feb 14, 2023	SELL	$4.56 - $6.61 $27,359 - $39,660	-6,000 Reduced 12.82%	40,800 $210,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.63 $14,625 - $25,857	-3,900 Reduced 7.69%	46,800 $289,000

146

102M

178K

159K

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $251M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.